Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Senktide** is a highly selective synthetic peptide agonist of the neurokinin 3 receptor (NK3R), a G protein-coupled receptor predominantly responsive to neurokinin B. It is derived from the C-terminal hexapeptide of substance P, with the sequence Suc-Asp-Phe-N(Me)Phe-Gly-Leu-Met-NH2 and notable modifications that confer high NK3R selectivity and resistance to enzymatic degradation. Senktide binds and activates NK3R, affecting neuroendocrine regulation by stimulating luteinizing hormone (LH) secretion via hypothalamic-pituitary-gonadal axis activation and is used experimentally to study reproductive function and neuroendocrine mechanisms. It also facilitates episodic-like memory in preclinical models and supports the development of novel therapeutic agents for reproductive and cognitive disorders[2][3][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on senktide.